PharmaLex Talks15 Maalis 2023

17: Gaining efficiencies with custom statistical solutions in a GxP setting

Summary:
A lot of statistical work within pharmaceutical companies is repetitive and this costs money and resources, especially if it’s done within GxP environments where there is often a need for double programming, extensive data quality control and meticulous follow-up of procedures. The podcast explores requirements and ways to develop fully automated solutions and processes to address this repetition and improve overall business efficiency.

Speaker:
Davor Josipovic is senior manager statistics and data science at PharmaLex, focusing on developing innovative solutions for questions the pharmaceutical industry faces, using applied mathematics, probabilistic modelling and machine learning.

Links:
General page:
https://www.pharmalex.com/pharmalex-departments/data-science-in-pharmaceutical-industry/

Custom solutions:
https://www.pharmalex.com/software-login/

Tämä jakso on lisätty Podme-palveluun avoimen RSS-syötteen kautta eikä se ole Podmen omaa tuotantoa. Siksi jakso saattaa sisältää mainontaa.

Jaksot(37)

5: Getting Ready for the IVDR

IVDR Brings Huge Change to Manufacturers Distributing Products in Europe The In Vitro Diagnostic Regulation (IVDR) means enormous upheaval for companies, as now up to 90% of products will need to be r...

11 Maalis 202214min

4: The Why, How, When and What of EU MDR Regulation

Jean has extended experience in all phases of the product lifecycle, driving compliance from concept initiation through to commercialisation and post-market support. He provides Regulatory and Qualit...

4 Helmi 202215min

3: Bayesian Statistics

This episode of PharmaLex Talks features Bruno Boulanger, Senior Director, Global Head Statistics and Data Science at PharmaLex and an award-wining author on Global Statistics and Data Science (link h...

29 Marras 202132min

2: Challenges & Regulatory landscape for ATMPs

Industry experts on ATMPs discuss the challenges and regulatory landscape with respect to the development of ATMPs, and what support and guidance is available from regulatory agencies.

15 Marras 202117min

1: Post Brexit landscape for the pharmaceutical industry

Meeting the regulatory challenges of the post-Brexit pharma landscape In the inaugural PharmaLex Talks podcast, host Elizabeth Hunt chats with Charley Maxwell, Director QMC / Senior Consultant at Ph...

6 Syys 202114min